MocetinostatA potent inhibitor of HDAC1, HDAC2, HDAC3, and HDAC11

Mocetinostat (CAS 726169-73-9)

Mocetinostat | CAS 726169-73-9 is rated 5.0 out of 5 by 1.
  • y_2019, m_9, d_23, h_9
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_364539, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 115ms
  • REVIEWS, PRODUCT
Synonym: MGCD0103
Application: A potent inhibitor of HDAC1, HDAC2, HDAC3, and HDAC11
CAS Number: 726169-73-9
Purity: ≥98%
Molecular Weight: 396.44
Molecular Formula: C23H20N6O
Supplemental Information: This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

Mocetinostat, MGCD0103 potently inhibits a subset of the nine human recombinant HDACs, including HDAC1, HDAC2, HDAC3, and HDAC11. MGCD0103 reveals most potent inhibitory activity against human HDAC1 and HDAC2 enzymes in vitro, and it does not inhibit class II HDACs. The inhibitory activity of MGCD0103 reaches the maximum plateau at 6 μM, and the maximal inhibitable enzyme pool affected by MGCD0103 is 75% of the total enzyme activity in HCT116 cells.

Appearance :
Powder
Physical State :
Solid
Storage :
Store at -20° C
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
Transport :
UN 2811, Class 6.1, Packing group III
PubChem CID :
9865515
SMILES :
C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC3=NC=CC(=N3)C4=CN=CC=C4

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

Mocetinostat  Product Citations

See how others have used Mocetinostat. Click on the entry to view the PubMed entry .

Citations 1 to 2 of 2 total

PMID: # 27249803  Agudelo, M. et al. 2016. PLoS ONE. 11: e0156421.

PMID: # 26519528  Stammler, D. et al. 2015. J. Immunol. 195: 5421-31.

Citations 1 to 2 of 2 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 79ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Borbely et al Borbely et al. (PubMed ID 26378038) found that HDAC inhibitor mocetinostat changed in gene expression resulting in suppression of genes involved in cell-cycle regulation in breast cancer cells. -SCBT Publication Review
Date published: 2015-06-19
  • y_2019, m_9, d_23, h_9
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_364539, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 32ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.